Natriuretic peptides: The feline experience

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 4, 2010, Pages 559-570

  Connolly, David J ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Clinical utility; Congestive heart failure; Feline cardiomyopathy; Natriuretic peptides; Respiratory distress

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; PEPTIDE HORMONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

CARDIOMYOPATHY; CAT DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART DISEASE; HEART HYPERTROPHY; HEART MURMUR; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HYPERTENSION; KIDNEY DYSFUNCTION; LABORATORY DIAGNOSIS; MYOCARDIAL DISEASE; NONHUMAN; PROGNOSIS; RADIOIMMUNOASSAY; REFERENCE VALUE; RESPIRATORY DISTRESS; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CAT; CAT DISEASES; FEMALE; MALE; VETERINARY;

FELIDAE;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAT DISEASES; CATS; FEMALE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 77954043427     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.03.003     Document Type: Review

References (64)

1. Martinez-Rumayor A., Richards A.M., Burnett J.C., et al. Biology of the natriuretic peptides. Am J Cardiol 2009, 101:3-8.
2. Wilkins M.R., Redondo J., Brown L.A. The natriuretic-peptide family. Lancet 1997, 349:1307-1310.
3. Arteaga E., Araujo A.Q., Buck P., et al. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 2005, 150:1228-1232.
4. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997, 96:509-516.
5. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004, 44:1328-1333.
6. Jefferies J.L., Denfield S.W., Price J.F., et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol 2006, 27:402-407.
7. Sudoh T., Kangawa K., Minamino N., et al. A new natriuretic peptide in porcine brain. Nature 2004, 332:78-81.
8. Yan W., Wu F., Morser J., et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000, 97:8525-8529.
9. Sawada Y., Suda M., Yokoyama H., et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997, 272:20545-20554.
10. Hunt P.J., Espiner E.A., Nicholls M.G., et al. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997, 18:1475-1481.
11. Biondo A.W., Ehrhart E.J., Sisson D.D., et al. Immunohistochemistry of atrial and brain natriuretic peptides in control cats and cats with hypertrophic cardiomyopathy. Vet Pathol 2003, 40:501-506.
12. Sisson D.D. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract 2004, 34:1105-1126.
13. Liu Z.L., Wiedmeyer C.E., Sisson D.D., et al. Cloning and characterisation of feline brain natriuretic peptide. Gene 2002, 292:183-190.
14. Biondo A.W., Liu Z.L., Wiedmeyer C.E., et al. Genomic sequence and cardiac expression of atrial natriuretic peptide in cats. Am J Vet Res 2002, 63:236-240.
15. Sisson D.D., Oyama M.A., Solter P.F. Plasma levels of ANP, BNP, epinephrine, norepinephrine, serum aldosterone, and plasma renin activity in healthy cats and cats with myocardial disease [abstract]. J Vet Intern Med 2003, 17:438.
16. Sisson D.D. B-type natriuretic peptides. J Vet Cardiol 2009, 11(S1):S5-7.
17. MacLean H.N., Abbott J.A., Ward D.L., et al. N-terminal natriuretic peptide immunoreactivity in plasma of cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006, 20:284-289.
18. Connolly D.J., Magalhaes R.J., Syme H.M., et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008, 22:96-105.
19. Fox F.P., Oyama M.A., Reynolds C., et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol 2009, 11(S1):S51-62.
20. Hsu A., Kittleson M.D., Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009, 11(S1):S63-70.
21. Zimmering T.M., Meneses F., Nolte I.J., et al. Measurement of N-terminal proatrial natriuretic peptide in plasma of cats with and without cardiomyopathy. Am J Vet Res 2009, 70:216-222.
22. Fox P.R., Oyama M.A., MacDonald K., et al. Assessment of NT-proBNP concentration in asymptomatic cats with cardiomyopathy [abstract]. J Vet Intern Med 2008, 22:719.
23. Wess G., Daisenberger P., Hirschberger J., et al. The utility of NT-proBNP to detect early stages of hypertrophic cardiomyopathy in cats and to differentiate disease stages [abstract]. J Vet Intern Med 2009, 23:687.
24. Carrier A., Beardow A., Farace G., et al. Analytical validation of a commercially available feline N-terminal prohormone brain natriuretic peptide ELISA [abstract]. J Vet Intern Med 2009, 23:747.
25. Lalor S.M., Connolly D.J., Elliott J., et al. Plasma concentrations of natriuretic peptides in normal cats and hypertensive cats with chronic kidney disease. J Vet Cardiol 2009, 11(S1):S71-9.
26. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. Am J Cardiol 2001, 37:379-385.
27. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
28. Mehra M.R., Maisel A. B-type natriuretic peptide in heart failure: diagnostic, prognostic and therapeutic use. Crit Pathw Cardiol 2005, 4:10-20.
29. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
30. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation 2002, 106:416-422.
31. Morrison L.K., Harrison A., Krishnaswamy P., et al. Utility of rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002, 39:202-209.
32. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654.
33. Wess G., Daisenberger P., Hirschberger J. The utility of NT-proBNP to differentiate cardiac and respiratory causes of dyspnea in cats [abstract]. J Vet Intern Med 2008, 22:707-708.
34. Connolly D.J., Magalhaes R.J., Fuentes V.L., et al. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 2009, 11(S1):S41-50.
35. Richards M., Nicholls M.G., Espiner E.A., et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease chronic coronary artery disease. J Am Coll Cardiol 2006, 47:52-60.
36. Luchner A., Hengstenberg C., Lowel H., et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005, 46:118-123.
37. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement. Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Am Coll Cardiol 2006, 47:91-97.
38. McCullough P.A., Kuncheria J., Mathur V.S. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med 2003, 4:S3-12.
39. McCullough P.A., Duc P., Omland T., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003, 41:571-579.
40. deFillippi C.R., Seliger S.L., Maynard S., et al. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007, 53:1511-1519.
41. McCullough P.A., Sandberg K.R. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003, 8:355-358.
42. van Kimmenade R.R., Januzzi J.L., Baggish A., et al. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure. J Am Coll Cardiol 2006, 48:1621-1627.
43. Bruch A., Reinecke H., Stypmann J., et al. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 2006, 25:1135-1141.
44. Boswood A., Dukes-McEwan J., Loureiro J., et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2008, 49:26-32.
45. Schmidt M.K., Reynolds C.A., Estrada A.H., et al. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: a pilot study. J Vet Cardiol 2009, 11(S1):S81-86.
46. Syme H.M., Markwell P.J., Pfeiffer D., et al. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. J Vet Intern Med 2006, 20:528-535.
47. Taylor J.A., Christenson R.H., Rao K., et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular diastolic pressure. Am Heart J 2006, 152:1071-1076.
48. Horwich T.B., Fonarow G.C., Hamilton M.A., et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001, 38:789-795.
49. Van Kimmenade R., van Dielen F., Bakker J. Is brain natriuretic peptide production decreased in obese subjects?. J Am Coll Cardiol 2006, 47:886-887.
50. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002, 40:976-982.
51. Dentali F., Donadini M., Gianni M. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med 2009, 4:123-128.
52. Shah K.B., Nolan M.M., Rao K., et al. The characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients. Am J Med 2007, 120:1071-1077.
53. Ozmen B., Ozmen D., Parildar Z., et al. Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr Res 2007, 32:1-8.
54. Ettinger S, Beardow A. Cardiac biomarkers measured in 500 cats with heart disease, heart failure and other diseases. In: Programs and abstracts of the 27th American College of Veterinary Internal Medicine Conference. Montreal, June 3-6, 2009.
55. Boswood A. The rise and fall of the cardiac biomarker. J Vet Intern Med 2004, 18:797-799. [editorial].
56. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
57. Maisel A.P., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
58. Januzzi J.L., Sakhuja R., O'Donoghue M., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006, 166:315-320.
59. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002, 106:2913-2918.
60. Omland T., Richards A.M., Wergeland R., et al. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 2005, 95:24-28.
61. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
62. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007, 49:1733-1739.
63. Paige C.F., Abbott J.A., Elvinger F., et al. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009, 234:1398-1403.
64. Belew A.M., Barlett T., Brown S.A. Evaluation of then white coat-effect in cats. J Vet Intern Med 1999, 13:134-142.